Aurinia Pharmaceuticals Inc [AUPH] stock is trading at $8.30, up 2.85%. An important factor to consider is whether the stock is rising or falling in short-term value. The AUPH shares have gain 6.14% over the last week, with a monthly amount glided 8.36%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Aurinia Pharmaceuticals Inc [NASDAQ: AUPH] stock has seen the most recent analyst activity on November 04, 2022, when Oppenheimer downgraded its rating to a Perform. On December 10, 2021, upgrade upgraded it’s rating to Outperform and revised its price target to $31 on the stock. Oppenheimer downgraded its rating to a Perform but stick to its price target of $32 on October 28, 2021. H.C. Wainwright reiterated its recommendation of a Buy and raised its price target to $35 on January 25, 2021. H.C. Wainwright reiterated a Buy rating for this stock on November 03, 2020, and downed its price target to $28. In a note dated June 17, 2020, BTIG Research initiated an Buy rating and provided a target price of $20 on this stock.
Aurinia Pharmaceuticals Inc [AUPH] stock has fluctuated between $5.11 and $10.67 over the past year. Currently, Wall Street analysts expect the stock to reach $10.75 within the next 12 months. Aurinia Pharmaceuticals Inc [NASDAQ: AUPH] shares were valued at $8.30 at the most recent close of the market. An investor can expect a potential return of 29.52% based on the average AUPH price forecast.
Analyzing the AUPH fundamentals
Aurinia Pharmaceuticals Inc [NASDAQ:AUPH] reported sales of 247.30M for the trailing twelve months, which represents a growth of 24.18%. Gross Profit Margin for this corporation currently stands at 0.88% with Operating Profit Margin at 0.13%, Pretax Profit Margin comes in at 0.17%, and Net Profit Margin reading is 0.16%. To continue investigating profitability, this company’s Return on Assets is posted at 0.08, Equity is 0.11 and Total Capital is 0.07. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.22.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Aurinia Pharmaceuticals Inc’s Current Ratio is 5.93. On the other hand, the Quick Ratio is 5.26, and the Cash Ratio is 0.97. Considering the valuation of this stock, the price to sales ratio is 4.53, the price to book ratio is 3.26 and price to earnings (TTM) ratio is 30.05.
Transactions by insiders
Recent insider trading involved Keenan Greg, Chief Medical Officer, that happened on Mar 07 ’25 when 8305.0 shares were sold. Chief Executive Officer, Greenleaf Peter completed a deal on Mar 03 ’25 to sell 0.2 million shares. Meanwhile, Chief Executive Officer Greenleaf Peter sold 0.16 million shares on Mar 04 ’25.
